Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Synergistic Effect of Vedolizumab and Pentoxifylline in the Management of Patients With Inflammatory Bowel Disease

Next Previous
X
Search
Trial Profile

Synergistic Effect of Vedolizumab and Pentoxifylline in the Management of Patients With Inflammatory Bowel Disease

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 06 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pentoxifylline (Primary) ; Vedolizumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 May 2021 Results assessing the combination of pentoxifylline and vedolizumab in patients with crohn's disease is safe and demonstrates improved response compared to vedolizumab monotherapy, presented at the Digestive Disease Week 2021.
    • 09 Jul 2019 Status changed from active, no longer recruiting to completed.
    • 16 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 15 Jul 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top